Navigation Links
CNA Finance Initiates Research Coverage On NuLife Sciences
Date:8/23/2017

CNA Finance Chief Research Analyst, Kenny Soulstring, today announced that the stock market news outlet had initiated coverage on NuLife Sciences. According to Soulstring, NuLife Sciences may be on the verge of causing a transformational shift in the organ transplant industry, focused on kidney transplant technology that integrates proprietary recellularization processes intended to eliminate the need for patients use of anti-rejection medication and dialysis treatment.

Soulstring believes that NuLife is well positioned from a strategic standpoint, targeting the treatment of not only the approximate 31,000 organ transplant cases per year but also looking to mark and treat the remaining 120,000 plus patients that are waiting in line. With promising results already demonstrated in animal studies, Soulstring believes that NuLife can take advantage of a market plagued with both logistical and organ donor match problems.

According to Soulstring, NuLife Sciences is advancing quickly and is combining ambition with solid results. He said that the NuLife Sciences difference stands in the process used, "The patented NULF recellularizing process takes particular hematopoietic cells that are used in the process and adds proprietary temperature and pressure factors. Through the associated vacuum process, specific cells get released from platelets without complete platelet degranulation. Coupled with those first two steps, the negative pressure created by the vacuum pulls the growth factors out of the platelets and puts it directly into the plasma. Then, once processed, the cells get reintroduced into the recipient with the intent of influencing the further growth of an already implanted and recellularized organ. Results from the animal studies have been extremely encouraging, and the swine kidneys used in the trial should provide reliable data, as they most closely resemble the kidney to that of humans. Thus, in the recently announced initiation of their pre-clinical study, NULF hopes to demonstrate that after the novel decellularization program, the creation of a kidney scaffold was produced upon which a new organ, unique to the recipient may get successfully rebuilt."

Soulstring thinks that NuLife Sciences is well beyond just providing a means to offer a transformational shift in the organ transplant industry. According to Soulstring, "NuLife may be in an enviable position to save hundreds of lives per year and at the same time introduce revolutionary applications from its proprietary processes that may eventually benefit an entire industry, thus saving thousands of lives per year and many millions of dollars in patient and industry cost."

To read CNA Finance's complete research coverage on NuLife Sciences, click here.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14621282.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
2. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
3. Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer
4. ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria
5. iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare
6. Neurotez Engages Invictus Global Capital as Corporate Finance & Capital Markets Advisors
7. Revenue Leak Soon Turns to Flood: Payment Penalties for High Infection Rates Draining Hospital Finances
8. Yew Bio-Pharm Group Signs Sales Agreement and Receives Subsidy Grant from the Finance Department of Heilongjiang Province, China
9. Oxford Finance Closes $20 Million Debt Facility with Inhibrx
10. Oxford Finance Provides $10 Million Debt Financing to Celula
11. CSM Appoints Michael Morse as Vice President of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... , ... September 17, 2019 , ... Tucker, a Labrador ... only four months old, Tucker was limping and lame on his right hip and ... dysplasia and it was called “the worst case the vet had seen.” He was ...
(Date:9/17/2019)... ... September 16, 2019 , ... ... with the China Focus @ Biotech Week Boston, a forum organized by MyBioGate, ... in healthcare innovation. , After a careful process of evaluation, twelve companies out ...
(Date:9/9/2019)... ... September 09, 2019 , ... Visikol CEO Dr. Michael Johnson ... focused on how best to characterize 3D cell culture models. The inherent problem of ... too thick and opaque to image through and therefore traditional wide-field or even confocal ...
(Date:8/29/2019)... ROCHESTER, N.Y. (PRWEB) , ... August 29, 2019 ... ... within a chronic disease affecting grapevines, a feat they hope will ultimately help ... products. , Researchers including several Rochester Institute of Technology faculty and alumni sequenced ...
Breaking Biology Technology:
(Date:8/27/2019)... ... August 26, 2019 , ... Shoreline Biome , ... strain level, has hired Bill McKenzie as its CEO and Karen Woodward as its ... Shoreline Biome meet growing demand for its products and expand the company’s sales worldwide. ...
(Date:8/27/2019)... ... August 27, 2019 , ... Ambry Genetics ... improve genetic testing guidelines. In the largest cohort study of its kind, Ambry ... at-risk patients. , Clinicians use guidelines to inform decisions about which patients ...
(Date:8/25/2019)... ... 2019 , ... Sierra Instruments is pleased to announce that their redesigned website ... live. Sierra has redesigned entry to the site with both engineers and those new ... to navigate with streamlined menus and simple access to resources and information on products ...
Breaking Biology News(10 mins):